A late-stage clinical win can change the trading character of a biotech stock in a matter of minutes. Kodiak Sciences Inc. ($KOD) shares surged as much as 90% in premarket trading Monday after the company reported positive results from its Phase 3 DAYBREAK study in wet age-related macular degeneration, or AMD.

The initial move is dramatic, but the more important question for traders may be what happens after the first burst of enthusiasm. A 90% premarket surge puts follow-through, liquidity, options activity and the market’s interpretation of the clinical result directly in focus.

Why the DAYBREAK result matters

DAYBREAK is a Phase 3 study evaluating a treatment for wet AMD. Positive data at this late stage can become a major catalyst because Phase 3 results represent an important clinical milestone for a biotechnology company. The headline result gives the market a new piece of information to assess: whether the program’s development trajectory may support a different view of Kodiak Sciences.

That does not automatically determine the stock’s next move. Biotech trading often separates the initial reaction from the follow-through. The first wave may reflect fast-moving repositioning around the headline, while subsequent trading can show whether broader market participation develops.

The reported premarket reaction — shares up as much as 90% — establishes the scale of the catalyst. Traders may now look for evidence that the market can absorb the move while continuing to evaluate the DAYBREAK results.

Follow-through is the next test

For $KOD, the immediate issue is not simply whether the stock reacts to positive news. It is whether the reaction develops into sustained attention. Trading volume, price stability after the opening, and the ability of the shares to hold interest beyond the initial announcement could shape the short-term setup.

Options activity may also draw attention. A sharp premarket move can make derivatives positioning more relevant as traders assess changing expectations and potential volatility. The assignment does not provide specific options data, so the key point is simply that activity in the options market may become an area of observation rather than a confirmed signal.

Another potential focus is read-across to other companies operating in ophthalmology and the AMD space. Positive late-stage data from one company may prompt market participants to revisit comparable development programs or sector assumptions. That does not establish a direct impact on any other company, but it can expand the scope of the market’s attention beyond Kodiak Sciences itself.

Goldman Sachs adds a measured counterweight

Goldman Sachs resumed coverage of Kodiak Sciences with a Neutral rating and a $36 price target. That stance introduces a measured counterpoint to the stock’s sharp premarket reaction. The rating and target do not erase the significance of the DAYBREAK result, but they signal that the market may continue weighing the clinical milestone against the broader valuation and development picture.

Goldman Sachs also described the biotech backdrop as constructive, citing mergers and acquisitions, clinical wins and easier regulation. Those factors may provide a supportive context for companies producing meaningful clinical updates. Still, a constructive backdrop is not the same as a guaranteed outcome for any individual stock.

The bottom line for traders

Kodiak Sciences has delivered the kind of catalyst that can command immediate attention: positive Phase 3 DAYBREAK results and a premarket move of as much as 90%. The next phase of the story may depend on whether trading activity remains orderly, whether the market continues to engage with the data, and how options and sector read-across develop.

The sharp move makes $KOD a stock to watch, but it also raises the standard for the information that follows. Traders may focus on the durability of the reaction rather than treating the first headline move as the complete story.